Align Technology announced strategic initiatives following discussions with Elliott Investment Management, including the appointment of three new independent directors to its Board of Directors with expertise in healthcare technology and global operations. The company engaged a leading consulting firm to conduct a comprehensive review aimed at enhancing commercial execution, margin expansion, and earnings growth. Additionally, Align increased its 2026 share repurchase commitment to $400 million–$500 million, reflecting management's confidence in the company's long-term value. These actions are intended to support sustainable revenue growth and capitalize on market opportunities in digital orthodontics and restorative dentistry.

Align Technology reported second quarter 2026 financial results with total revenues of $1.06 billion, a 4.3% year-over-year increase driven by record Clear Aligner shipments of 691.8 thousand cases and an 8.2% rise in segment revenue to $870.9 million. Non-GAAP diluted net income per share was $2.64, while GAAP results included a $37.5 million liability for UK VAT. The company announced fiscal 2026 full-year revenue growth guidance of 3% to 4%, with Clear Aligner volume expected to grow approximately 6%. Management also raised the 2026 stock repurchase target to $400–$500 million and provided preliminary outlook for fiscal 2027 operating margin expansion. Align Technology is a medical device company that designs, manufactures, and sells clear aligners, intraoral scanners, and CAD/CAM software for digital orthodontics.

Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer, resigned from Align Technology, Inc. effective August 1, 202key. Align Technology, Inc. operates in the medical device industry, providing clear aligner technology and clear aligner systems.

C. Raymond Larkin, Jr. notified the Board of Directors that he will retire as Chairman of the Board effective July 1, 2026, and will resign from the Board effective December 31, 2026. The resignation is not due to any disagreement regarding company operations, policies, or practices. Independent director Kevin Conroy has been appointed to succeed Mr. Larkin as Chairman, effective July 1, 2026. Align Technology, Inc. is a medical device company specializing in clear aligner systems.

Align Technology announced plans to repurchase $200 million of its common stock through open market transactions as part of its existing $1.0 billion repurchase program. This move signals the company's commitment to returning capital to shareholders and may provide support for earnings per share by reducing the total share count.